Biosenors nets CE Mark for smaller diameter DES
Biosensors International Group has received CE Mark approval for a 2.25-mm diameter version of its BioMatrix drug-eluting stent (DES) system, further expanding the currently available range of 2.5-mm to 4.0-mm stent diameters.

The new addition to the BioMatrix portfolio offers a major opportunity to increase market penetration, as an estimated 12 to 15 percent of PCI involve blood vessels with diameters of 2.5 mm or less, according to the Singapore-based company.

BioMatrix was originally launched in Europe in April 2008, with a proprietary coating formulation consisting of an abluminal biodegradable polymer and the Biolimus A9 drug, Biosensors. BioMatrix is now available in varying international markets outside of China, the U.S. and Japan.